Drug
Lnp023
Lnp023: highest development phase Phase 3, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| LNP023 NCT04578834 | Phase 3 | IgA Nephropathy |
Latest
No recent events.
Follow Lnp023 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.